HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
Kimio YonesakaJunko TanizakiOsamu MaenishiKoji HarataniHiasto KawakamiKaoru TanakaHidetoshi HayashiKazuko SakaiYasutaka ChibaAsuka TsuyaHiroki GotoEri OtsukaHiroaki OkidaMaki KobayashiRyoto YoshimotoMasanori FunabashiYuuri HashimotoKenji HirotaniTakashi KagariKazuto NishioKazuhiko NakagawaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
-mutated NSCLC.